Drug Profile

NKTR 422

Alternative Names: NKTR-422

Latest Information Update: 20 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nektar Therapeutics
Class Colony-stimulating factors; Proteins
Mechanism of Action Colony-stimulating factor receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders

Most Recent Events

14 Nov 2024 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Autoimmune disorders presented at the ACR Convergence 2024 (ACR-2024)
07 Nov 2024 Preclinical trials in Autoimmune disorders in USA (unspecified route)
07 Nov 2024 Nektar Therapeutics plans a clinical trial for Autoimmune disorders in 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com